Healthcare Industry News: Allergan
News Release - September 9, 2010
The Benefits of Crospon's EndoFLIP(R) System Presented at International Obesity Surgery Congress 2010Study highlights significant improvement in early weight loss after gastric band surgery
CARLSBAD, Calif. & GALWAY, Ireland--(Healthcare Sales & Marketing Network)--Crospon, an Irish medical device developer based in Galway, has announced results of a study presented at the 15th Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO 2010), in Long Beach, CA.
The study which took place at the Speciality Surgery Center of Fort Worth, TX, a Center of the AIGB True Results clinical network, the largest gastric band placement network in the world, under the direction of Principal Investigator Dr. Robert G. Snow, demonstrated that 30% of the patients measured achieved greater than 30% excess weight loss in the 4-6 week period after surgery. Even though they had a band adjustment during surgery, no patient required their band to be loosened in the post-operative period.
Crospon develops leading edge minimally invasive medical devices for monitoring, diagnosis and therapy in the gastroenterology area. Earlier this year Crospon launched its EndoFLIP® product in the U.S. market at the 12th World Congress of Endoscopic Surgery in National Harbor, Washington DC. The EndoFLIP® product which received FDA clearance in December 2009 is the first product of its kind, which allows a bariatric surgeon to measure and set a consistent gastric band stoma size during surgery.
Commenting, Dr. Robert Snow, Principal Investigator said, “The results of this study are changing the way we look at adjusting bands, in that we are no longer waiting until a month after surgery for the patient’s first band adjustment, so that they are now getting on a more aggressive weight loss trajectory straight after surgery. It is generally accepted that early weight loss is a good indicator for longer term success.”
Dr Snow continued, “Further studies are planned to assess whether the EndoFLIP® system can be used in a similar manner for post-operative band adjustment with a goal of reducing the number of adjustments by targeting a more precise adjustment each time”.
Speaking at the Congress, Larry Fulton, VP Sales for the Americas, Crospon said, “We are encouraged by the results of this study, and are currently introducing EndoFLIP® in a number of other leading gastric band centers. This study has shown how gastric band surgery can be improved to get patients losing weight more quickly by bringing science to the band adjustment procedure. Whereas the study used the Allergan LapBand®, the EndoFLIP® may be used with any gastric band. The study clearly demonstrated that improved early weight loss was achieved, but it remains to be seen if this translates into long term weight loss outcomes”.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.